Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891944247> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2891944247 endingPage "5007" @default.
- W2891944247 startingPage "5007" @default.
- W2891944247 abstract "5007 Background: Efficacy of PD-1 inhibition has not been demonstrated in large-scale mCRPC trials. Pembro showed preliminary antitumor activity in PD-L1+ mCRPC in KEYNOTE-028 (n = 23). Here, we present results from cohorts 1-3 (n = 258) of the phase 2 KEYNOTE-199 study of pembro monotherapy in docetaxel-refractory mCRPC (NCT02787005). Methods: Cohorts 1 (C1) and 2 (C2) enrolled patients (pts) with RECIST-measurable PD-L1+ and PD-L1– disease, respectively. C3 enrolled pts with nonmeasurable, bone-predominant disease. All pts had ECOG PS 0-2 and received ≥1 novel endocrine therapy (eg, abiraterone, enzalutamide) and 1-2 prior chemotherapies including docetaxel. Pts received pembro 200 mg Q3W until PD or intolerable toxicity. Response was assessed Q9W in yr 1, then Q12W. Primary end point was ORR per RECIST v1.1 by central review in C1 and C2, separately and combined. Key secondary end points included DCR (CR + PR + SD) per PCWG3-modifed RECIST and safety in all 3 cohorts. Results: 131 pts enrolled in C1, 67 in C2, and 60 in C3. Median follow-up as of Oct 13, 2017, was 8.1 mo, 7.9 mo, and 11.8 mo, respectively. Antitumor activity was observed in all cohorts (Table). Across cohorts, DCR lasting ≥6 mo was 11%. In C1 and C2, 9% of pts had a ≥30% decrease in target lesions; 48% had target lesion changes between –30% and +20%. The response rate was numerically higher in pts with somatic BRCA1/2 or ATM mutations (12%). Drug-related grade 3-5 AE rates were 13% in C1, 12% in C2, and 17% in C3. Conclusions: Pembro shows antitumor activity and disease control with acceptable safety in pts with docetaxel-refractory mCRPC, regardless of PD-L1 status, in both RECIST-measurable and nonmeasurable disease. These data support further evaluation of pembro in mCRPC, including in pts wth homologous recombination defects. Clinical trial information: NCT02787005. C1 C2 C3 C1+C2 C1+C2+C3 RECIST v1.1 ORR, % (95% CI 5 (2-11) 3 ( < 1-10) NA 5 (2-8) NA DCR, % (95% CI) 22 (15-30) 24 (14-36) 37 (25-50) 23 (17-29) 26 (21-32) DCR ≥6 mo, % (95% CI) 9 (5-16) 6 (2-15) 22 (12-34) 8 (5-13) 11 (8-16) PCWG3-modified RECIST ORR, % (95% CI) 5 (2-11) 3 ( < 1-10) NA 5 (2-8) NA DCR, % (95% CI) 27 (20-36) 42 (30-54) 57 (43-69) 32 (26-39) 38 (32-44) DCR ≥6 mo, % (95% CI) 11 (6-17) 9 (3-18) 30 (19-43) 10 (6-15) 15 (11-20)" @default.
- W2891944247 created "2018-09-27" @default.
- W2891944247 creator A5018436364 @default.
- W2891944247 creator A5018645768 @default.
- W2891944247 creator A5018801649 @default.
- W2891944247 creator A5031310463 @default.
- W2891944247 creator A5042022141 @default.
- W2891944247 creator A5054898066 @default.
- W2891944247 creator A5057407696 @default.
- W2891944247 creator A5070016877 @default.
- W2891944247 creator A5079046653 @default.
- W2891944247 date "2018-05-20" @default.
- W2891944247 modified "2023-10-16" @default.
- W2891944247 title "KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC)." @default.
- W2891944247 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.5007" @default.
- W2891944247 hasPublicationYear "2018" @default.
- W2891944247 type Work @default.
- W2891944247 sameAs 2891944247 @default.
- W2891944247 citedByCount "73" @default.
- W2891944247 countsByYear W28919442472018 @default.
- W2891944247 countsByYear W28919442472019 @default.
- W2891944247 countsByYear W28919442472020 @default.
- W2891944247 countsByYear W28919442472021 @default.
- W2891944247 countsByYear W28919442472022 @default.
- W2891944247 countsByYear W28919442472023 @default.
- W2891944247 crossrefType "journal-article" @default.
- W2891944247 hasAuthorship W2891944247A5018436364 @default.
- W2891944247 hasAuthorship W2891944247A5018645768 @default.
- W2891944247 hasAuthorship W2891944247A5018801649 @default.
- W2891944247 hasAuthorship W2891944247A5031310463 @default.
- W2891944247 hasAuthorship W2891944247A5042022141 @default.
- W2891944247 hasAuthorship W2891944247A5054898066 @default.
- W2891944247 hasAuthorship W2891944247A5057407696 @default.
- W2891944247 hasAuthorship W2891944247A5070016877 @default.
- W2891944247 hasAuthorship W2891944247A5079046653 @default.
- W2891944247 hasConcept C121332964 @default.
- W2891944247 hasConcept C121608353 @default.
- W2891944247 hasConcept C126322002 @default.
- W2891944247 hasConcept C142424586 @default.
- W2891944247 hasConcept C143998085 @default.
- W2891944247 hasConcept C203092338 @default.
- W2891944247 hasConcept C2776421732 @default.
- W2891944247 hasConcept C2776551883 @default.
- W2891944247 hasConcept C2777701055 @default.
- W2891944247 hasConcept C2780057760 @default.
- W2891944247 hasConcept C2780192828 @default.
- W2891944247 hasConcept C2781190966 @default.
- W2891944247 hasConcept C535046627 @default.
- W2891944247 hasConcept C61367390 @default.
- W2891944247 hasConcept C71924100 @default.
- W2891944247 hasConcept C87355193 @default.
- W2891944247 hasConceptScore W2891944247C121332964 @default.
- W2891944247 hasConceptScore W2891944247C121608353 @default.
- W2891944247 hasConceptScore W2891944247C126322002 @default.
- W2891944247 hasConceptScore W2891944247C142424586 @default.
- W2891944247 hasConceptScore W2891944247C143998085 @default.
- W2891944247 hasConceptScore W2891944247C203092338 @default.
- W2891944247 hasConceptScore W2891944247C2776421732 @default.
- W2891944247 hasConceptScore W2891944247C2776551883 @default.
- W2891944247 hasConceptScore W2891944247C2777701055 @default.
- W2891944247 hasConceptScore W2891944247C2780057760 @default.
- W2891944247 hasConceptScore W2891944247C2780192828 @default.
- W2891944247 hasConceptScore W2891944247C2781190966 @default.
- W2891944247 hasConceptScore W2891944247C535046627 @default.
- W2891944247 hasConceptScore W2891944247C61367390 @default.
- W2891944247 hasConceptScore W2891944247C71924100 @default.
- W2891944247 hasConceptScore W2891944247C87355193 @default.
- W2891944247 hasIssue "15_suppl" @default.
- W2891944247 hasLocation W28919442471 @default.
- W2891944247 hasOpenAccess W2891944247 @default.
- W2891944247 hasPrimaryLocation W28919442471 @default.
- W2891944247 hasRelatedWork W122177069 @default.
- W2891944247 hasRelatedWork W1512914561 @default.
- W2891944247 hasRelatedWork W1652439388 @default.
- W2891944247 hasRelatedWork W1996389184 @default.
- W2891944247 hasRelatedWork W2077244514 @default.
- W2891944247 hasRelatedWork W2135620818 @default.
- W2891944247 hasRelatedWork W2400161037 @default.
- W2891944247 hasRelatedWork W2568045406 @default.
- W2891944247 hasRelatedWork W2602837880 @default.
- W2891944247 hasRelatedWork W2982156914 @default.
- W2891944247 hasVolume "36" @default.
- W2891944247 isParatext "false" @default.
- W2891944247 isRetracted "false" @default.
- W2891944247 magId "2891944247" @default.
- W2891944247 workType "article" @default.